Percutaneous sensitization with allergens through barrier-disrupted skin elicits a Th2-dominant cytokine response.
about
Expression of the C-C chemokine MIP-3 alpha/CCL20 in human epidermis with impaired permeability barrier functionThe Skin as a Route of Allergen Exposure: Part I. Immune Components and Mechanisms.Epigenetics in human autoimmunity. Epigenetics in autoimmunity - DNA methylation in systemic lupus erythematosus and beyond.Asthma-like airway inflammation and responses in a rat model of atopic dermatitis induced by neonatal capsaicin treatment.Microneedle-based transcutaneous immunisation in mice with N-trimethyl chitosan adjuvanted diphtheria toxoid formulations.Atopic dermatitis results in intrinsic barrier and immune abnormalities: implications for contact dermatitis.Intranasally administered antigen 85B gene vaccine in non-replicating human Parainfluenza type 2 virus vector ameliorates mouse atopic dermatitis.Filaggrin genotype in ichthyosis vulgaris predicts abnormalities in epidermal structure and functionRole of macrophage migration inhibitory factor (MIF) in pollen-induced allergic conjunctivitis and pollen dermatitis in mice.Influence of the route of exposure and the matrix on the sensitisation potency of a major cows' milk allergen.Epicutaneous immunization with type II collagen inhibits both onset and progression of chronic collagen-induced arthritisSkin barrier disruption: a requirement for allergen sensitization?What is living on your dog's skin? Characterization of the canine cutaneous mycobiota and fungal dysbiosis in canine allergic dermatitis.Potential mechanisms for the association between fall birth and food allergyAntigen-driven bystander effect accelerates epicutaneous sensitization with a new protein allergen.Chinese herbal medicine research in eczema treatmentFilaggrin mutations and atopy: consequences for future therapeutics.Atopic dermatitis and the stratum corneum: part 3: the immune system in atopic dermatitis.Anti-hapten antibodies in response to skin sensitization.Epicutaneous immunotherapy for food allergy as a novel pathway for oral tolerance induction.Mechanisms of anti-carcinogenesis by indole-3-carbinol. Studies of enzyme induction, electrophile-scavenging, and inhibition of aflatoxin B1 activationAllergic host defences.Debates in allergy medicine: Molecular allergy diagnosis with ISAC will replace screenings by skin prick test in the future.Lipoteichoic acid from Staphylococcus aureus enhances allergen-specific immunoglobulin E production in mice.Effect of the lactic acid bacterium Streptococcus thermophilus on stratum corneum ceramide levels and signs and symptoms of atopic dermatitis patients.Thymic stromal lymphopoietin expression is increased in the horny layer of patients with atopic dermatitis.Stratum corneum removal facilitates experimental sensitization to mite allergens in atopic dogs.Stratum corneum adhesive tape stripping: influence of anatomical site, application pressure, duration and removal.Immune response against 2,4-dinitrofluorobenzene-induced atopic dermatitis-like clinical manifestation is suppressed by spermidine in NC/Nga mice.Percutaneous application of peptidoglycan from Staphylococcus aureus induces mast cell development in mouse spleen.Lipoteichoic acid from Staphylococcus aureus induces Th2-prone dermatitis in mice sensitized percutaneously with an allergen.Improvement of atopic dermatitis and reduction of skin allergic responses by oral intake of konjac ceramide.
P2860
Q28216686-CE5180E5-77A5-40FE-8668-4DC2A356BCABQ30274806-C37CA565-E273-4E7B-875B-F80A24E85793Q33643660-6C1118A3-78C5-47AA-8CB9-DE98515A69B9Q33719258-4ABDBB01-FD09-44DC-A2C6-5BCAFAB9AA26Q34059945-9A503275-5200-4D14-BF9F-435DD7B41A40Q34797596-727B81C0-0B73-4AED-A899-DDD801D8359CQ34812205-0AED1C62-810A-4936-A832-E67B8BC44C8EQ34838614-1A5799DF-77DF-42C2-B4B5-33315DA93D36Q35043911-0CF1BB96-75F1-422D-94BC-BF8C69D3600DQ35066096-D7CD65EF-5C07-474C-BD8F-EC58AF989AAFQ35745027-D59F1646-C643-4D87-92C1-B56F6216FAA5Q35757285-D3CA0577-1E35-4B49-9134-BD73B07D9DFCQ35834057-42C60CF2-94DA-4268-8E58-9EB94726C0EDQ35951681-92BFE2AB-8F2E-4B55-B8C5-FF36081E5AEDQ37130369-228C3BF7-C4A6-4D36-82BF-8569EDF9E3A2Q37869938-11949708-1093-4AD0-AA6D-967FD03B877EQ37979847-00C70582-42BD-460C-9A98-22C195986351Q38207032-DA822926-5EA7-4DA4-93F8-29BCF3FC436FQ38631246-43F22C4F-2364-43BF-B7B0-136DAAD49675Q38638657-497F9271-5012-4E05-B8DC-81ACBB0AD76DQ41177694-6B0018A6-F758-47C3-ADEA-93CFB295C8F2Q41190858-7056E9CA-DA39-431D-8DFC-A92D3DD430B7Q41681635-49266F4D-DE88-420B-9E4D-052965A936C9Q44474650-D61285AE-AC71-4A0D-B8B8-1D0B83875624Q44713593-081CDD68-8F22-40E9-BC95-F653E2452328Q44728300-4F9AE4A3-5D05-465B-9793-FE20589D8DDEQ44859320-E39DABB7-EA81-432E-A2EF-F8DC7C895C03Q46440515-435CCB29-70A7-4FEF-AE8E-9E1979FC6C25Q46778513-87C462C1-7CD9-4629-90C4-FCC0BFD37A53Q46954543-D0BB30C8-7CFA-4809-84EA-735109E2F608Q52546011-AB0A08E1-396B-4290-8EF0-C961C03F9D39Q55042337-E3663B2A-42DC-4CE6-9CD0-69EEB5E7BB95
P2860
Percutaneous sensitization with allergens through barrier-disrupted skin elicits a Th2-dominant cytokine response.
description
1998 nî lūn-bûn
@nan
1998 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի մարտին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Percutaneous sensitization wit ...... h2-dominant cytokine response.
@ast
Percutaneous sensitization wit ...... h2-dominant cytokine response.
@en
Percutaneous sensitization wit ...... h2-dominant cytokine response.
@nl
type
label
Percutaneous sensitization wit ...... h2-dominant cytokine response.
@ast
Percutaneous sensitization wit ...... h2-dominant cytokine response.
@en
Percutaneous sensitization wit ...... h2-dominant cytokine response.
@nl
prefLabel
Percutaneous sensitization wit ...... h2-dominant cytokine response.
@ast
Percutaneous sensitization wit ...... h2-dominant cytokine response.
@en
Percutaneous sensitization wit ...... h2-dominant cytokine response.
@nl
P2093
P2860
P1476
Percutaneous sensitization wit ...... h2-dominant cytokine response.
@en
P2093
P2860
P304
P356
10.1002/(SICI)1521-4141(199803)28:03<769::AID-IMMU769>3.0.CO;2-H
P407
P577
1998-03-01T00:00:00Z